{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:54:38Z","timestamp":1791323678333,"version":"4.3.1"},"reference-count":72,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008497","name":"Boston Scientific Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100029590","name":"Chinese American Physician Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100029590","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016304","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016304","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jvir.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Vascular and Interventional Radiology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jvir.2026.108928","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T15:38:23Z","timestamp":1783006703000},"page":"108928","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Medical Therapies for Vascular Anomalies: What Interventional Radiologists Need to Know"],"prefix":"10.1016","volume":"37","author":[{"given":"Hamidreza","family":"Rouientan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iman","family":"Kiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8829-1548","authenticated-orcid":false,"given":"Nariman","family":"Nezami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3847-3925","authenticated-orcid":false,"given":"Nassir","family":"Rostambeigi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7184-0275","authenticated-orcid":false,"given":"Mohadese","family":"Ahmadzade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Ghasemi-Rad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9993-3801","authenticated-orcid":false,"given":"Shahram","family":"Akhlaghpoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvir.2026.108928_bib1","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1161\/CIRCRESAHA.121.319587","article-title":"Vascular and lymphatic malformations: perspectives from human and vertebrate studies","volume":"129","author":"Janardhan","year":"2021","journal-title":"Circ Res"},{"key":"10.1016\/j.jvir.2026.108928_bib2","article-title":"Estimate of the prevalence of vascular malformations","volume":"4","author":"Penington","year":"2023","journal-title":"J Vasc Anom (Phila)"},{"key":"10.1016\/j.jvir.2026.108928_bib3","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13023-024-03018-y","article-title":"Factors affecting the ability of patients with complex vascular anomalies to navigate the healthcare system","volume":"19","author":"Sisk","year":"2024","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jvir.2026.108928_bib4","article-title":"Updated classification of vascular anomalies. A living document from the International Society for the Study of Vascular Anomalies Classification Group","volume":"6","author":"Goldenberg","year":"2025","journal-title":"J Vasc Anom (Phila)"},{"key":"10.1016\/j.jvir.2026.108928_bib5","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1001\/archfaci.2011.795","article-title":"Current knowledge and management of vascular anomalies, II: malformations","volume":"13","author":"Hochman","year":"2011","journal-title":"Arch Facial Plast Surg"},{"key":"10.1016\/j.jvir.2026.108928_bib6","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20130392","article-title":"Vascular anomalies: classification, imaging characteristics and implications for interventional radiology treatment approaches","volume":"87","author":"Mulligan","year":"2014","journal-title":"Br J Radiol"},{"key":"10.1016\/j.jvir.2026.108928_bib7","doi-asserted-by":"crossref","first-page":"448","DOI":"10.2340\/00015555-2300","article-title":"Efficacy and safety of mammalian target of rapamycin inhibitors in vascular anomalies: a systematic review","volume":"96","author":"Nadal","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jvir.2026.108928_bib8","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.det.2021.12.009","article-title":"Systemic therapy for vascular anomalies and the emergence of genotype-guided management","volume":"40","author":"Nicholson","year":"2022","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jvir.2026.108928_bib9","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.ijwd.2021.10.014","article-title":"Targeted treatment of vascular anomalies","volume":"7","author":"Ng","year":"2021","journal-title":"Int J Womens Dermatol"},{"key":"10.1016\/j.jvir.2026.108928_bib10","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/j.1349-7006.2007.00439.x","article-title":"Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis","volume":"98","author":"Kobayashi","year":"2007","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jvir.2026.108928_bib11","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.3324\/haematol.2020.261859","article-title":"An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study","volume":"106","author":"Al-Samkari","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.jvir.2026.108928_bib12","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1136\/jnis-2024-022908","article-title":"Sclerotherapy combined with sirolimus for the treatment of complex cervicofacial lymphatic malformations in infants: avoiding the need for tracheostomy","volume":"18","author":"Qi","year":"2025","journal-title":"J Neurointerv Surg"},{"key":"10.1016\/j.jvir.2026.108928_bib13","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.3390\/biomedicines12061289","article-title":"Defining the role of oral pathway inhibitors as targeted therapeutics in arteriovenous malformation care","volume":"12","author":"Mansur","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.jvir.2026.108928_bib14","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1055\/s-0037-1604297","article-title":"Advances in the medical management of vascular anomalies","volume":"34","author":"Ricci","year":"2017","journal-title":"Semin Intervent Radiol"},{"key":"10.1016\/j.jvir.2026.108928_bib15","article-title":"The VASCERN-VASCA Working Group diagnostic and management pathways for venous malformations","volume":"4","author":"Dompmartin","year":"2023","journal-title":"J Vasc Anom (Phila)"},{"key":"10.1016\/j.jvir.2026.108928_bib16","first-page":"97","article-title":"Diagnosis and treatment of venous malformations. consensus document of the International Union of Phlebology (IUP): updated 2013","volume":"34","author":"Lee","year":"2015","journal-title":"Int Angiol"},{"key":"10.1016\/j.jvir.2026.108928_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvir.2026.108588","article-title":"Incidence of bleomycin-induced hyperpigmentation in patients undergoing sclerotherapy for low-flow vascular malformations","volume":"37","author":"Tregobov","year":"2026","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.jvir.2026.108928_bib18","article-title":"Effectiveness and safety of sirolimus in the treatment of venous malformations: a meta-analysis of prospective studies","volume":"13","author":"Wang","year":"2025","journal-title":"J Vasc Surg Venous Lymphat Disord"},{"key":"10.1016\/j.jvir.2026.108928_bib19","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jamadermatol.2021.3459","article-title":"Sirolimus (rapamycin) for slow-flow malformations in children: the observational-phase randomized clinical PERFORMUS trial","volume":"157","author":"Maruani","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jvir.2026.108928_bib20","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.173095","article-title":"Preliminary results of the European multicentric phase III trial regarding sirolimus in slow-flow vascular malformations","volume":"8","author":"Seront","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.jvir.2026.108928_bib21","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jvs.2019.06.217","article-title":"Efficacy and safety of sirolimus in the treatment of vascular anomalies: a systematic review","volume":"71","author":"Freixo","year":"2020","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.jvir.2026.108928_bib22","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1161\/CIRCRESAHA.121.318145","article-title":"Genetic basis and therapies for vascular anomalies","volume":"129","author":"Queisser","year":"2021","journal-title":"Circ Res"},{"key":"10.1016\/j.jvir.2026.108928_bib23","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/ncponc1112","article-title":"Rapamycin treatment for a child with germline PTEN mutation","volume":"5","author":"Marsh","year":"2008","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.jvir.2026.108928_bib24","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.14309\/ajg.0000000000001117","article-title":"Efficacy and safety of sirolimus for blue rubber bleb nevus syndrome: a prospective study","volume":"116","author":"Zhou","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jvir.2026.108928_bib25","first-page":"1105","article-title":"Efficacy and tolerance of sirolimus (rapamycin) for extracranial arteriovenous malformations in children and adults","volume":"99","author":"Gabeff","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jvir.2026.108928_bib26","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/cts.13488","article-title":"Clinical differences in sirolimus treatment with low target levels between children and adults with vascular malformations\u2014a nationwide trial","volume":"16","author":"Harbers","year":"2023","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jvir.2026.108928_bib27","doi-asserted-by":"crossref","DOI":"10.1111\/ped.70002","article-title":"Sirolimus treatment for intractable vascular anomalies (SIVA): an open-label, single-arm, multicenter, prospective trial","volume":"67","author":"Ozeki","year":"2025","journal-title":"Pediatr Int"},{"key":"10.1016\/j.jvir.2026.108928_bib28","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2015-3257","article-title":"Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies","volume":"137","author":"Adams","year":"2016","journal-title":"Pediatrics"},{"key":"10.1016\/j.jvir.2026.108928_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.23736\/S0392-9590.22.04902-1","article-title":"Guidelines for Vascular Anomalies by the Italian Society for the study of Vascular Anomalies (SISAV)","volume":"41","author":"Stillo","year":"2022","journal-title":"Int Angiol"},{"key":"10.1016\/j.jvir.2026.108928_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2023.100969","article-title":"Alpelisib for treatment of patients with PIK3CA-related overgrowth spectrum (PROS)","volume":"25","author":"Canaud","year":"2023","journal-title":"Genet Med"},{"key":"10.1016\/j.jvir.2026.108928_bib31","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1080\/08880018.2025.2498660","article-title":"Alpelisib in pediatric PIK3CA- and TIE-2-mutant vascular anomalies: a case series on safety, efficacy, and drug exposure","volume":"42","author":"Etingin","year":"2025","journal-title":"Pediatr Hematol Oncol"},{"key":"10.1016\/j.jvir.2026.108928_bib32","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1007\/s00381-024-06290-2","article-title":"Progressive vascular tumor in infant: a case report and literature review of PIK3CA vascular malformation","volume":"40","author":"Medina","year":"2024","journal-title":"Childs Nerv Syst"},{"key":"10.1016\/j.jvir.2026.108928_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2021.732836","article-title":"PIK3CA-related overgrowth spectrum from diagnosis to targeted therapy: a case of CLOVES syndrome treated with alpelisib","volume":"9","author":"Pagliazzi","year":"2021","journal-title":"Front Pediatr"},{"key":"10.1016\/j.jvir.2026.108928_bib34","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20212148","article-title":"Treatment of two infants with PIK3CA-related overgrowth spectrum by alpelisib","volume":"219","author":"Morin","year":"2022","journal-title":"J Exp Med"},{"key":"10.1016\/j.jvir.2026.108928_bib35","article-title":"Adverse events of alpelisib compassionate treatment in pros","volume":"6","author":"Triana","year":"2025","journal-title":"J Vasc Anom (Phila)"},{"key":"10.1016\/j.jvir.2026.108928_bib36","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jaad.2018.09.050","article-title":"Use of topical rapamycin in the treatment of superficial lymphatic malformations","volume":"80","author":"Garc\u00eda-Montero","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jvir.2026.108928_bib37","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1186\/s13063-019-3767-8","article-title":"Topical sirolimus 0.1% for treating cutaneous microcystic lymphatic malformations in children and adults (TOPICAL): protocol for a multicenter phase 2, within-person, randomized, double-blind, vehicle-controlled clinical trial","volume":"20","author":"Leducq","year":"2019","journal-title":"Trials"},{"key":"10.1016\/j.jvir.2026.108928_bib38","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.anl.2019.11.008","article-title":"Management of extracranial arteriovenous malformations of the head and neck","volume":"47","author":"Fern\u00e1ndez-Alvarez","year":"2020","journal-title":"Auris Nasus Larynx"},{"key":"10.1016\/j.jvir.2026.108928_bib39","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1055\/s-0037-1604299","article-title":"New treatment approaches to arteriovenous malformations","volume":"34","author":"Gilbert","year":"2017","journal-title":"Semin Intervent Radiol"},{"key":"10.1016\/j.jvir.2026.108928_bib40","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/pde.15224","article-title":"An overview of interventional radiology techniques for the diagnosis and management of vascular anomalies: part 2","volume":"40","author":"Scollan","year":"2023","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jvir.2026.108928_bib41","article-title":"Angiographic evidence of response to trametinib therapy for a spinal cord arteriovenous malformation","volume":"2","author":"Cooke","year":"2021","journal-title":"J Vasc Anom (Phila)"},{"key":"10.1016\/j.jvir.2026.108928_bib42","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1200\/JCO.2025.43.16_suppl.3096","article-title":"Monocentric pilot trial of trametinib in severe extracranial arteriovenous malformations","volume":"43","author":"Seront","year":"2025","journal-title":"Am Soc Clin Oncol"},{"key":"10.1016\/j.jvir.2026.108928_bib43","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jpeds.2022.05.030","article-title":"Trametinib for refractory chylous effusions and systemic complications in children with Noonan syndrome","volume":"248","author":"Nakano","year":"2022","journal-title":"J Pediatr"},{"key":"10.1016\/j.jvir.2026.108928_bib44","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1177\/1078155220975825","article-title":"A drug repositioning success: the repositioned therapeutic applications and mechanisms of action of thalidomide","volume":"27","author":"Amare","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.jvir.2026.108928_bib45","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.3390\/jcm13185404","article-title":"The role of thalidomide and its analogs in the treatment of hereditary hemorrhagic telangiectasia: a systematic review","volume":"13","author":"Ugur","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.jvir.2026.108928_bib46","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s44161-022-00080-2","article-title":"Case report study of thalidomide therapy in 18 patients with severe arteriovenous malformations","volume":"1","author":"Boon","year":"2022","journal-title":"Nat Cardiovasc Res"},{"key":"10.1016\/j.jvir.2026.108928_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110114","article-title":"Recent advances in the molecular mechanism of thalidomide teratogenicity","volume":"127","author":"Gao","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jvir.2026.108928_bib48","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1080\/14740338.2021.1991307","article-title":"Thalidomide: history, withdrawal, renaissance, and safety concerns","volume":"20","author":"Vargesson","year":"2021","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jvir.2026.108928_bib49","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.jvir.2025.03.011","article-title":"Transarterial embolization for pulmonary arteriovenous malformation: a systematic review and meta-analysis","volume":"36","author":"Yu","year":"2025","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.jvir.2026.108928_bib50","doi-asserted-by":"crossref","first-page":"989","DOI":"10.7326\/M20-1443","article-title":"Second international guidelines for the diagnosis and management of hereditary hemorrhagic telangiectasia","volume":"173","author":"Faughnan","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jvir.2026.108928_bib51","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejim.2023.05.020","article-title":"Potential angiogenic biomarkers in hereditary hemorrhagic telangiectasia and other vascular diseases","volume":"115","author":"Villanueva","year":"2023","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jvir.2026.108928_bib52","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1001\/jama.2012.250","article-title":"Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output","volume":"307","author":"Dupuis-Girod","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jvir.2026.108928_bib53","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.mayocp.2017.11.013","article-title":"Intravenous bevacizumab for refractory hereditary hemorrhagic telangiectasia-related epistaxis and gastrointestinal bleeding","volume":"93","author":"Iyer","year":"2018","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jvir.2026.108928_bib54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jvir.2016.09.024","article-title":"Radioembolization of hepatic malignancies: background, quality improvement guidelines, and future directions","volume":"28","author":"Padia","year":"2017","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.jvir.2026.108928_bib55","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.jvir.2009.01.022","article-title":"Wound dehiscence or failure to heal following venous access port placement in patients receiving bevacizumab therapy","volume":"20","author":"Zawacki","year":"2009","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.jvir.2026.108928_bib56","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10456-018-9646-1","article-title":"Pazopanib may reduce bleeding in hereditary hemorrhagic telangiectasia","volume":"22","author":"Faughnan","year":"2019","journal-title":"Angiogenesis"},{"key":"10.1016\/j.jvir.2026.108928_bib57","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa2312749","article-title":"Pomalidomide for epistaxis in hereditary hemorrhagic telangiectasia","volume":"391","author":"Al-Samkari","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvir.2026.108928_bib58","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nm.2131","article-title":"Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia","volume":"16","author":"Lebrin","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.jvir.2026.108928_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmg.2022.104517","article-title":"The VASCERN-VASCA working group diagnostic and management pathways for severe and\/or rare infantile hemangiomas","volume":"65","author":"Diociaiuti","year":"2022","journal-title":"Eur J Med Genet"},{"key":"10.1016\/j.jvir.2026.108928_bib60","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2018-3475","article-title":"Clinical practice guideline for the management of infantile hemangiomas","volume":"143","author":"Krowchuk","year":"2019","journal-title":"Pediatrics"},{"key":"10.1016\/j.jvir.2026.108928_bib61","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa1404710","article-title":"A randomized, controlled trial of oral propranolol in infantile hemangioma","volume":"372","author":"L\u00e9aut\u00e9-Labr\u00e8ze","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvir.2026.108928_bib62","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s00431-025-06631-6","article-title":"The VASCERN-VASCA diagnostic and management pathways for kaposiform hemangioendothelioma","volume":"185","author":"Gasparella","year":"2025","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.jvir.2026.108928_bib63","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1002\/ijc.30216","article-title":"Treatment of kaposiform hemangioendothelioma and tufted angioma","volume":"139","author":"Liu","year":"2016","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jvir.2026.108928_bib64","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jaad.2025.03.023","article-title":"Efficacy and safety of high-vs low-dose sirolimus in patients with kaposiform hemangioendothelioma: a randomized clinical trial","volume":"93","author":"Zhou","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jvir.2026.108928_bib65","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood.2021014027","article-title":"Sirolimus plus prednisolone vs sirolimus monotherapy for kaposiform hemangioendothelioma: a randomized clinical trial","volume":"139","author":"Ji","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jvir.2026.108928_bib66","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jpeds.2013.03.080","article-title":"Consensus-derived practice standards plan for complicated kaposiform hemangioendothelioma","volume":"163","author":"Drolet","year":"2013","journal-title":"J Pediatr"},{"key":"10.1016\/j.jvir.2026.108928_bib67","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1055\/s-0044-1791205","article-title":"Imaging of vascular anomalies","volume":"41","author":"Gayou","year":"2024","journal-title":"Semin intervent Radiol"},{"key":"10.1016\/j.jvir.2026.108928_bib68","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1055\/s-0044-1791204","article-title":"What the interventional radiologist needs to know about the genetics of vascular anomalies","volume":"41","author":"Josephs","year":"2024","journal-title":"Semin Intervent Radiol"},{"key":"10.1016\/j.jvir.2026.108928_bib69","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s13023-024-03196-9","article-title":"Assessment of gene-disease associations and recommendations for genetic testing for somatic variants in vascular anomalies by VASCERN-VASCA","volume":"19","author":"Revencu","year":"2024","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jvir.2026.108928_bib70","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1182\/hematology.2024000598","article-title":"Molecular landscape and classification of vascular anomalies","volume":"2024","author":"Seront","year":"2024","journal-title":"Hematology"},{"key":"10.1016\/j.jvir.2026.108928_bib71","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/s43856-025-01174-1","article-title":"Harnessing liquid biopsy to unveil RAS-MEK pathway somatic pathogenic variants in extracranial arterio-venous malformations","volume":"5","author":"Bhatia","year":"2025","journal-title":"Commun Med"},{"key":"10.1016\/j.jvir.2026.108928_bib72","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.14829","article-title":"Barriers to genetic testing in vascular malformations","volume":"6","author":"Borst","year":"2023","journal-title":"JAMA Netw Open"}],"container-title":["Journal of Vascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1051044326009395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1051044326009395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:49:14Z","timestamp":1791323354000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1051044326009395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":72,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1051044326009395"],"URL":"https:\/\/doi.org\/10.1016\/j.jvir.2026.108928","relation":{},"ISSN":["1051-0443"],"issn-type":[{"value":"1051-0443","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medical Therapies for Vascular Anomalies: What Interventional Radiologists Need to Know","name":"articletitle","label":"Article Title"},{"value":"Journal of Vascular and Interventional Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvir.2026.108928","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 SIR, 2026","name":"copyright","label":"Copyright"}],"article-number":"108928"}}